Limited coverage criteria – infliximab for rheumatoid arthritis
Last updated on February 24, 2026
PharmaCare covers infliximab biosimilar products for psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PsO), Crohn's disease (CD), ulcerative colitis (UC) and rheumatoid arthritis (RA).
Return to Special Authority drug list
Generic name |
infliximab |
||
Brand name |
Strength |
Form |
|
| Avsola™ | 100 mg/vial | powder for solution | |
| Inflectra© | 100 mg/vial | powder for solution | |
| Ixifi© | 100 mg/vial | powder for solution | |
| Remdantry™ | 100 mg/vial | powder for solution | |
| Remsima™SC | 120 mg/mL | pre-filled pen for subcutaneous injection | |
| Renflexis© | 100 mg/vial | powder for solution | |
Special Authority criteria |
Approval period |
|---|---|
|
For the treatment of rheumatoid arthritis according to established criteria as described on Special Authority request forms below, when requested by a rheumatologist |
Initial: 1 year Renewal: 1 year to indefinite |
Practitioner exemptions
- None
Special notes
- PharmaCare covers a maximum 56-day supply of intravenous (IV) infliximab per fill. Eligible dosing amounts can be seen on the Special Authority Request forms and on an approved Special Authority Request. One infusion (dose) usually provides treatment for 56 days or less
- PharmaCare coverage is limited to maintenance dosages of subcutaneous (SC) infliximab 120 mg every 2 weeks. PharmaCare covers a maximum 28-day supply of subcutaneous infliximab per fill